29
Participants
Start Date
September 27, 2022
Primary Completion Date
November 19, 2024
Study Completion Date
November 19, 2024
ISB 1442 SC injection escalating doses
Participants will receive escalating SC doses of ISB 1442
ISB 1442 SC injection at RP2D
ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met
Royal Prince Albert Hospital: Institute of Haematology, Camperdown
The Alfred Hospital-Melbourne, Melbourne
St. Vincent's Hospital Melbourne, Fitzroy
Gold Coast University Hospital, Southport
Pindara Private Hospital, Benowa
One Clinical Research Pty Ltd, Nedlands
New York-Presbyterian /Weill Cornell Medical Center - The Myeloma Center, New York
University of Miami - Sylvester Comprehensive Cancer Center, Miami
Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center - Main Campus, Detroit
Froedtert Hospital & The Medical College of Wisconsin, Milwaukee
The University of Chicago Medical Center (UCMC) Duchossois Center for Advanced Medicine (DCAM), Chicago
Washington University School of Medicine - Siteman Cancer Center, St Louis
Health Care Global Enterprises Limited (HCG), Bangalore
M S Ramaiah Medical College & Hospital, Bangalore
Max Super Speciality Hospital, Delhi
Lead Sponsor
Ichnos Sciences SA
INDUSTRY